In the phase 3 EMERGENT-2 and EMERGENT-3 trials, Cobenfy met its primary end point, showing statistically significant ...
The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, ...
Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...
Researchers conducted a cohort study to assess the predictive value of plasma MMP9 in antipsychotic treatment response among patients with schizophrenia.
On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...
Zacks.com on MSN2d
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY GainsAbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...
2don MSN
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
AbbVie shares dropped nearly 10% after its schizophrenia drug emraclidine failed in late ... in the change from baseline in ...
For patients with schizophrenia, repetitive transcranial magnetic stimulation (rTMS) was effective and safe in treating ...
Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two ...
AbbVie's emraclidine trials for schizophrenia fail, leading to stock decline, but analysts maintain confidence in the company ...
The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback